This is a summary of the European public assessment report (EPAR) for Resolor. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Resolor.
Therapeutic Indication
### Therapeutic indication Resolor is indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief.
Therapeutic Area (MeSH)
N/AATC Code
A06AX05
ATC Item
prucalopride
Pharmacotherapeutic Group
Other drugs for constipation
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| Prucalopride succinate | N/A | 普芦卡必利 |
EMA Name
Resolor
Medicine Name
Resolor
Aliases
N/ANo risk management plan link.
